Hong Kong-based biotech company Insilico Medicine has announced the launch of COVIDomic, a research support platform tailored to the Covid-19 pandemic.
COVIDomic enables scientists to use integrated anonymised patient data with a variety of existing data sets, before applying bioinformatics and artificial intelligence (AI). The platform is intended to help stratify Covid-19 patients more effectively, as well as understanding the disease trajectory and identifying relevant disease pathways and targets.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Insilico Medicine founder and CEO Alex Zhavoronkov said: “COVIDomic is an open access tool to stratify risk and severity from multimodal data sets, including multi-omics data. Insilico Medicine’s AI-driven generative biology approach is a unique offering in the marketplace. We are part of many Covid-19 consortiums and collaborations but COVIDomic is a system that will help scientists and researchers alike to predict the severity of the disease.”
